Back

Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy

1 September 2024 (11:00 - 11:30)
Organised by: Logo
Congress Presentation Part of: Rhythm control for atrial fibrillation: procedures and outcomes Catheter Ablation of Arrhythmias ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Anne Wang Gottlieb

Karolinska University Hospital, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Same-day discharge after atrial fibrillation ablation: is it equally safe?
Doctor A. Abrantes (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Transoesophageal echocardiography-guided cardioversion and thromboembolism.
Doctor M. Lunden (Norrkoping, SE)
Abstract Slides Video
Presentation thumbnail
Disparities in the access to atrial fibrillation ablation in Denmark
Doctor C. Zoerner (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Comparison of complications during catheter ablation of atrial fibrillation between radiofrequency and cryoballoon ablation: insights from a nation-wide claims-based database
Doctor K. Miyamoto (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Procedural findings and follow-up results of catheter ablation of atrial fibrillation in patients after radiation therapy for breast cancer
Doctor M. Tydecks (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Rhythm control for atrial fibrillation: procedures and outcomes

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Follow-up outcomes of atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: a single-center analysis
thumbnail
Congress Presentation
The impact of the catheter ablation on long-term prognosis in patients with hypertrophic cardiomyopathy and atrial fibrillation
thumbnail
Congress Presentation
Contemporary outcomes of patients with hypertrophic cardiomyopathy and atrial fibrillation: a nationwide matched cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources